Trinity Biotech

Trinity Biotech Market capitalization

The The market capitalization of Trinity Biotech (TRIB) as of Nov 10, 2026 is 14.35 M USD. In the previous year, The market capitalization was 14.35 M USD — a change of 0.00% (lower).

Market capitalization

14.35 MUSD

YoY

0.00%

Last updated:

In 2025, Trinity Biotech's market cap stood at 14.35 M USD, a 0.00% increase from the 14.35 M USD market cap in the previous year.

The Trinity Biotech Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market capitalization
Date
Market capitalization
Jan 1, 2018
14.35 M USD
Jan 1, 2019
14.35 M USD
Jan 1, 2020
14.35 M USD
Jan 1, 2021
14.35 M USD
Jan 1, 2022
14.35 M USD
Jan 1, 2023
14.35 M USD
Jan 1, 2024
14.35 M USD
Jan 1, 2025
14.35 M USD
The Trinity Biotech Market capitalization history
YEARMarket capitalizationYoY
14.35 MUSD0.00%
14.35 MUSD0.00%
14.35 MUSD0.00%
14.35 MUSD0.00%
14.35 MUSD0.00%
14.35 MUSD0.00%
14.35 MUSD0.00%
14.35 MUSD0.00%
14.35 MUSD0.00%
14.35 MUSD0.00%
14.35 MUSD0.00%
14.35 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring Trinity Biotech's Market Capitalization

Trinity Biotech's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Trinity Biotech's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Trinity Biotech's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Trinity Biotech’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Trinity Biotech stock

The market capitalization of Trinity Biotech is 14.35 M USD in 2025.

The market capitalization of Trinity Biotech changed from 14.35 M USD to 14.35 M USD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The market capitalization Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.

Number of shares * share price = market capitalization

To evaluate The market capitalization's USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare The market capitalization's Trinity Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Trinity Biotech

All Key Metrics — Trinity Biotech